Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-13 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
17/07/25	8.650 $	+0.58%	2,699
16/07/25	8.600 $	-2.11%	2,651
15/07/25	8.785 $	-2.93%	3,818
14/07/25	9.050 $	+1.80%	5,725
11/07/25	8.890 $	-1.33%	2,522

Delayed Quote Nasdaq, July 17, 2025 at 03:56 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.600USD

Average target price

150.00USD

Spread / Average Target

+1,644.19%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq Other stock markets 19:57:12 17/07/2025 BST			5-day change	1st Jan Change
8.650 ^USD	+0.58%		-4.00%	-62.02%

07-08	Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation	RE
07-08	Quoin Pharmaceuticals Ltd. Announces Mutual Separation with CFO Gordon Dunn	CI

Capitalization	5.06M 4.33M 4.03M 3.76M 6.93M 434M 7.73M 48.93M 18.43M 204M 18.97M 18.58M 746M	P/E ratio 2025 *	-0.32x	P/E ratio 2026 *	-0.55x
Enterprise value	5.06M 4.33M 4.03M 3.76M 6.93M 434M 7.73M 48.93M 18.43M 204M 18.97M 18.58M 746M	EV / Sales 2025 *	-	EV / Sales 2026 *	0.77x
Free-Float	11.82%	Yield 2025 *	-	Yield 2026 *	-

Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation	07-08	RE
Quoin Pharmaceuticals Ltd. Announces Mutual Separation with CFO Gordon Dunn	07-08	CI
Quoin Pharmaceuticals Ltd. Releases New Netherton Now Video Featuring Professor Mellerio, International Expert in Genetic Skin Diseases	06-26	CI
Quoin Pharmaceuticals Ltd. Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome	06-24	CI
Certain Warrants of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Certain Options of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Certain American Depositary Shares of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Certain Ordinary Shares of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical Study	05-22	CI
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study	05-22	RE
Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study	05-22	MT
Quoin Says Early Preliminary Results From Pediatric Skin Disorder Trial Therapy Shows 'Clear Evidence' of Healing	05-14	MT
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study	05-14	CI

Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating	15/03/24	MT
JMP Securities Lowers Quoin Pharmaceuticals' Price Target to $6 From $15, Maintains Market Outperform Rating	10/03/23	MT
Ladenburg Thalmann Downgrades Quoin Pharmaceuticals to Neutral From Buy	10/03/23	MT
Alliance Global Partners Initiates Coverage on Quoin Pharmaceuticals With Buy Rating, $20 Price Target	07/09/22	MT
Ladenburg Lowers Quoin Pharmaceuticals' Price Target to $12 From $25, Maintains Buy Rating	23/08/22	MT

Quoin Pharmaceuticals, Ltd. Share Price

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Valuation: Quoin Pharmaceuticals, Ltd.

Chart: Quoin Pharmaceuticals, Ltd.

Latest news: Quoin Pharmaceuticals, Ltd.

Analysts' recommendations: Quoin Pharmaceuticals, Ltd.

Press Releases: Quoin Pharmaceuticals, Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Quoin Pharmaceuticals, Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases	06-26	AQ
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome	06-24	AQ
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study	05-22	AQ
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome	05-20	AQ
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO - Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge - More Stocks Inside	05-15	AQ

1 day	+2.38%
1 week	-2.57%
Current month	-4.89%
1 month	+5.38%
3 months	+60.23%
6 months	-56.09%
Current year	-61.46%

1 week	8.53	9.2
1 month	8.04	9.86
Current year	5.01	28.35
1 year	5.01	54.95
3 years	5.01	11,806.22
5 years	5.01	70,638.86
10 years	5.01	70,638.86

Manager	Title	Age	Since
Denise Carter COO	Chief Operating Officer	56	27/10/2021
Michael Myers CEO	Chief Executive Officer	63	27/10/2021
Gordon Dunn DFI	Director of Finance/CFO	61	31/10/2021

Director	Title	Age	Since
Michael Myers CHM	Chairman	63	27/10/2021
Denise Carter BRD	Director/Board Member	56	27/10/2021
Dennis Langer BRD	Director/Board Member	74	27/10/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
QUOIN PHARMACEUTICALS, LTD.	+2.38%	-2.57%	-62.68%	-99.60%	5.06M
LONZA GROUP AG	-0.26%	-0.18%	+11.63%	+1.03%	50.48B
BEONE MEDICINES LTD.	+3.33%	+14.20%	+88.35%	+67.52%	33.07B
CELLTRION, INC.	+2.04%	+2.44%	+4.40%	+9.85%	28.19B
IQVIA HOLDINGS INC.	+1.62%	-2.99%	-30.27%	-24.56%	27.44B
EUROFINS SCIENTIFIC SE	+0.53%	+0.26%	+25.84%	-22.49%	12.65B
ICON PUBLIC LIMITED COMPANY	+1.09%	-4.66%	-56.58%	-29.08%	11.45B
ASCENDIS PHARMA A/S	+0.19%	-0.51%	+26.71%	+105.36%	10.62B
QIAGEN N.V.	-0.08%	-0.76%	+10.27%	-1.52%	10.46B
TEMPUS AI, INC.	+2.25%	+2.50%	+53.30%	-	10.38B
Average	+1.30%	+0.15%	+7.10%	+0.72%	19.47B
Weighted average by Cap.	+1.23%	+1.74%	+17.59%	+12.88%

	2025 *	2026 *
Net sales	-	6.53M 5.59M 5.2M 4.85M 8.94M 560M 9.98M 63.14M 23.78M 263M 24.48M 23.98M 962M
Net income	-16.05M -13.75M -12.79M -11.92M -21.98M -1.38B -24.52M -155M -58.46M -646M -60.19M -58.94M -2.37B	-10.52M -9.01M -8.38M -7.82M -14.4M -903M -16.07M -102M -38.31M -423M -39.45M -38.63M -1.55B
Net Debt	-	-